Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress

In vivo demonstration with magnetic resonance imaging

Hanrui Zhang, Brandon Morgan, Barry J. Potter, Lixin Ma, Kevin C Dellsperger, Zoltan Ungvari, Cuihua Zhang

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Resveratrol is a natural phytophenol that exhibits cardioprotective effects. This study was designed to elucidate the mechanisms by which resveratrol protects against diabetes-induced cardiac dysfunction. Normal control (m-Leprdb) mice and type 2 diabetic (Leprdb) mice were treated with resveratrol orally for 4 wk. In vivo MRI showed that resveratrol improved cardiac function by increasing the left ventricular diastolic peak filling rate in Leprdb mice. This protective role is partially explained by resveratrol's effects in improving nitric oxide (NO) production and inhibiting oxidative/nitrative stress in cardiac tissue. Resveratrol increased NO production by enhancing endothelial NO synthase (eNOS) expression and reduced O2- production by inhibiting NAD(P)H oxidase activity and gp91phox mRNA and protein expression. The increased nitrotyrosine (N-Tyr) protein expression in Leprdb mice was prevented by the inducible NO synthase (iNOS) inhibitor 1400W. Resveratrol reduced both N-Tyr and iNOS expression in Leprdb mice. Furthermore, TNF-α mRNA and protein expression, as well as NF-κB activation, were reduced in resveratrol-treated Leprdb mice. Both Leprdb mice null for TNF-α (dbTNF-/dbTNF- mice) and Leprdb mice treated with the NF-κB inhibitor MG-132 showed decreased NAD(P)H oxidase activity and iNOS expression as well as elevated eNOS expression, whereas m-Leprdb mice treated with TNF-α showed the opposite effects. Thus, resveratrol protects against cardiac dysfunction by inhibiting oxidative/nitrative stress and improving NO availability. This improvement is due to the role of resveratrol in inhibiting TNF-α-induced NF-κB activation, therefore subsequently inhibiting the expression and activation of NAD(P)H oxidase and iNOS as well as increasing eNOS expression in type 2 diabetes.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume299
Issue number4
DOIs
StatePublished - Oct 1 2010

Fingerprint

Type 2 Diabetes Mellitus
Oxidative Stress
Magnetic Resonance Imaging
Nitric Oxide Synthase
NADPH Oxidase
Nitric Oxide
resveratrol
Messenger RNA
Proteins
Nitric Oxide Synthase Type III
Nitric Oxide Synthase Type II
Left Ventricular Function

Keywords

  • Anti-inflammation
  • Antioxidants and free radicals
  • Cardiac diabetic complication
  • Magnetic resonance spectroscopy
  • Nitric oxide

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress : In vivo demonstration with magnetic resonance imaging. / Zhang, Hanrui; Morgan, Brandon; Potter, Barry J.; Ma, Lixin; Dellsperger, Kevin C; Ungvari, Zoltan; Zhang, Cuihua.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 299, No. 4, 01.10.2010.

Research output: Contribution to journalArticle

@article{30c3e346d9cd4b099cb511b4843bdc80,
title = "Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: In vivo demonstration with magnetic resonance imaging",
abstract = "Resveratrol is a natural phytophenol that exhibits cardioprotective effects. This study was designed to elucidate the mechanisms by which resveratrol protects against diabetes-induced cardiac dysfunction. Normal control (m-Leprdb) mice and type 2 diabetic (Leprdb) mice were treated with resveratrol orally for 4 wk. In vivo MRI showed that resveratrol improved cardiac function by increasing the left ventricular diastolic peak filling rate in Leprdb mice. This protective role is partially explained by resveratrol's effects in improving nitric oxide (NO) production and inhibiting oxidative/nitrative stress in cardiac tissue. Resveratrol increased NO production by enhancing endothelial NO synthase (eNOS) expression and reduced O2•- production by inhibiting NAD(P)H oxidase activity and gp91phox mRNA and protein expression. The increased nitrotyrosine (N-Tyr) protein expression in Leprdb mice was prevented by the inducible NO synthase (iNOS) inhibitor 1400W. Resveratrol reduced both N-Tyr and iNOS expression in Leprdb mice. Furthermore, TNF-α mRNA and protein expression, as well as NF-κB activation, were reduced in resveratrol-treated Leprdb mice. Both Leprdb mice null for TNF-α (dbTNF-/dbTNF- mice) and Leprdb mice treated with the NF-κB inhibitor MG-132 showed decreased NAD(P)H oxidase activity and iNOS expression as well as elevated eNOS expression, whereas m-Leprdb mice treated with TNF-α showed the opposite effects. Thus, resveratrol protects against cardiac dysfunction by inhibiting oxidative/nitrative stress and improving NO availability. This improvement is due to the role of resveratrol in inhibiting TNF-α-induced NF-κB activation, therefore subsequently inhibiting the expression and activation of NAD(P)H oxidase and iNOS as well as increasing eNOS expression in type 2 diabetes.",
keywords = "Anti-inflammation, Antioxidants and free radicals, Cardiac diabetic complication, Magnetic resonance spectroscopy, Nitric oxide",
author = "Hanrui Zhang and Brandon Morgan and Potter, {Barry J.} and Lixin Ma and Dellsperger, {Kevin C} and Zoltan Ungvari and Cuihua Zhang",
year = "2010",
month = "10",
day = "1",
doi = "10.1152/ajpheart.00489.2010",
language = "English (US)",
volume = "299",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress

T2 - In vivo demonstration with magnetic resonance imaging

AU - Zhang, Hanrui

AU - Morgan, Brandon

AU - Potter, Barry J.

AU - Ma, Lixin

AU - Dellsperger, Kevin C

AU - Ungvari, Zoltan

AU - Zhang, Cuihua

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Resveratrol is a natural phytophenol that exhibits cardioprotective effects. This study was designed to elucidate the mechanisms by which resveratrol protects against diabetes-induced cardiac dysfunction. Normal control (m-Leprdb) mice and type 2 diabetic (Leprdb) mice were treated with resveratrol orally for 4 wk. In vivo MRI showed that resveratrol improved cardiac function by increasing the left ventricular diastolic peak filling rate in Leprdb mice. This protective role is partially explained by resveratrol's effects in improving nitric oxide (NO) production and inhibiting oxidative/nitrative stress in cardiac tissue. Resveratrol increased NO production by enhancing endothelial NO synthase (eNOS) expression and reduced O2•- production by inhibiting NAD(P)H oxidase activity and gp91phox mRNA and protein expression. The increased nitrotyrosine (N-Tyr) protein expression in Leprdb mice was prevented by the inducible NO synthase (iNOS) inhibitor 1400W. Resveratrol reduced both N-Tyr and iNOS expression in Leprdb mice. Furthermore, TNF-α mRNA and protein expression, as well as NF-κB activation, were reduced in resveratrol-treated Leprdb mice. Both Leprdb mice null for TNF-α (dbTNF-/dbTNF- mice) and Leprdb mice treated with the NF-κB inhibitor MG-132 showed decreased NAD(P)H oxidase activity and iNOS expression as well as elevated eNOS expression, whereas m-Leprdb mice treated with TNF-α showed the opposite effects. Thus, resveratrol protects against cardiac dysfunction by inhibiting oxidative/nitrative stress and improving NO availability. This improvement is due to the role of resveratrol in inhibiting TNF-α-induced NF-κB activation, therefore subsequently inhibiting the expression and activation of NAD(P)H oxidase and iNOS as well as increasing eNOS expression in type 2 diabetes.

AB - Resveratrol is a natural phytophenol that exhibits cardioprotective effects. This study was designed to elucidate the mechanisms by which resveratrol protects against diabetes-induced cardiac dysfunction. Normal control (m-Leprdb) mice and type 2 diabetic (Leprdb) mice were treated with resveratrol orally for 4 wk. In vivo MRI showed that resveratrol improved cardiac function by increasing the left ventricular diastolic peak filling rate in Leprdb mice. This protective role is partially explained by resveratrol's effects in improving nitric oxide (NO) production and inhibiting oxidative/nitrative stress in cardiac tissue. Resveratrol increased NO production by enhancing endothelial NO synthase (eNOS) expression and reduced O2•- production by inhibiting NAD(P)H oxidase activity and gp91phox mRNA and protein expression. The increased nitrotyrosine (N-Tyr) protein expression in Leprdb mice was prevented by the inducible NO synthase (iNOS) inhibitor 1400W. Resveratrol reduced both N-Tyr and iNOS expression in Leprdb mice. Furthermore, TNF-α mRNA and protein expression, as well as NF-κB activation, were reduced in resveratrol-treated Leprdb mice. Both Leprdb mice null for TNF-α (dbTNF-/dbTNF- mice) and Leprdb mice treated with the NF-κB inhibitor MG-132 showed decreased NAD(P)H oxidase activity and iNOS expression as well as elevated eNOS expression, whereas m-Leprdb mice treated with TNF-α showed the opposite effects. Thus, resveratrol protects against cardiac dysfunction by inhibiting oxidative/nitrative stress and improving NO availability. This improvement is due to the role of resveratrol in inhibiting TNF-α-induced NF-κB activation, therefore subsequently inhibiting the expression and activation of NAD(P)H oxidase and iNOS as well as increasing eNOS expression in type 2 diabetes.

KW - Anti-inflammation

KW - Antioxidants and free radicals

KW - Cardiac diabetic complication

KW - Magnetic resonance spectroscopy

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=77958026411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958026411&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00489.2010

DO - 10.1152/ajpheart.00489.2010

M3 - Article

VL - 299

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 4

ER -